FDA gives expedited approval to new groundbreaking pancreatic cancer drug
Summary
The FDA has quickly approved a new pill called daraxonrasib for the most common type of pancreatic cancer. This drug helps block a protein mutation that causes tumor growth, and patients taking it lived almost twice as long as those who received chemotherapy.Key Facts
- The drug daraxonrasib was given expedited approval by the FDA.
- It targets a mutated protein found in over 90% of pancreatic cancer cases.
- Patients using daraxonrasib lived a median of 13.2 months, compared to 6.7 months with chemotherapy.
- The drug is sold under the brand name Rasonque by Revolution Medicines.
- Pancreatic cancer is hard to detect early and has a low five-year survival rate of 13%.
- The drug acts like “molecular glue” to bind to mutated Ras proteins, which were previously considered untreatable.
- The FDA approved the drug more than six months ahead of schedule.
- Revolution Medicines is also testing this drug technology on other cancers such as lung cancer.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
